Unanswered questions in prostate cancer — findings of an international multi-stakeholder consensus by the PIONEER consortium

the PIONEER Consortium; Muhammad Imran Omar; Steven MacLennan; Maria J. Ribal; Monique J. Roobol; Konstantinos Dimitropoulos; Thomas van den Broeck; Sara J. MacLennan; Susan Evans Axelsson; Giorgio Gandaglia; Peter Paul Willemse; Ken Mastris; John Butler Ransohoff; Zsuzsanna Devecseri; Thomas Abbott; Bertrand De Meulder; Anders Bjartell; Alex Asiimwe; James N’Dow; Emma Smith; Karin Plass; Nicolas Mottet; Robert Shepherd; Lisa Moris; Michael Lardas; Nicola Fossati; Karl Pang; Riccardo Campi; Isabella Greco; Mauro Gacci; Sergio Serni; Ragnar Lonnerbro; Alberto Briganti; Daniele Crosti; Roberto Garzonio; Martina Faticoni; Chris Bangma; Eliza Roest; Arjan Breederland; Sebastiaan Remmers; Derya Tilki; Anssi Auvinen; Teemu Murtola; Tapio Visakorpi; Kirsi Talala; Teuvo Tammela; Aino Siltari; Mieke Van Hemelrijck; Katharina Beyer; Stephane Lejeune; Maxim Moinat

doi:10.1038/s41585-023-00748-9

Unanswered questions in prostate cancer — findings of an international multi-stakeholder consensus by the PIONEER consortium

the PIONEER Consortium, Muhammad Imran Omar^*, Steven MacLennan, Maria J. Ribal, Monique J. Roobol, Konstantinos Dimitropoulos, Thomas van den Broeck, Sara J. MacLennan, Susan Evans Axelsson, Giorgio Gandaglia, Peter Paul Willemse, Ken Mastris, John Butler Ransohoff, Zsuzsanna Devecseri, Thomas Abbott, Bertrand De Meulder, Anders Bjartell, Alex Asiimwe, James N’Dow, Emma SmithKarin Plass, Nicolas Mottet, Robert Shepherd, Lisa Moris, Michael Lardas, Nicola Fossati, Karl Pang, Riccardo Campi, Isabella Greco, Mauro Gacci, Sergio Serni, Ragnar Lonnerbro, Alberto Briganti, Daniele Crosti, Roberto Garzonio, Martina Faticoni, Chris Bangma, Eliza Roest, Arjan Breederland, Sebastiaan Remmers, Derya Tilki, Anssi Auvinen, Teemu Murtola, Tapio Visakorpi, Kirsi Talala, Teuvo Tammela, Aino Siltari, Mieke Van Hemelrijck, Katharina Beyer, Stephane Lejeune, Maxim Moinat

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

Abstract

PIONEER is a European network of excellence for big data in prostate cancer consisting of 37 private and public stakeholders from 9 countries across Europe. Many progresses have been done in prostate cancer management, but unanswered questions in the field still exist, and big data could help to answer these questions. The PIONEER consortium conducted a two-round modified Delphi survey aiming at building consensus between two stakeholder groups — health-care professionals and patients with prostate cancer — about the most important questions in the field of prostate cancer to be answered using big data. Respondents were asked to consider what would be the effect of answering the proposed questions on improving diagnosis and treatment outcomes for patients with prostate cancer and to score these questions on a scale of 1 (not important) to 9 (critically important). The mean percentage of participants who scored each of the proposed questions as critically important was calculated across the two stakeholder groups and used to rank the questions and identify the highest scoring questions in the critically important category. The identification of questions in prostate cancer that are important to various stakeholders will help the PIONEER consortium to provide answers to these questions to improve the clinical care of patients with prostate cancer.

Original language	English
Pages (from-to)	494-501
Number of pages	8
Journal	Nature Reviews Urology
Volume	20
Issue number	8
Early online date	3 Apr 2023
DOIs	https://doi.org/10.1038/s41585-023-00748-9
Publication status	Published - Aug 2023

Bibliographical note

Funding Information:
PIONEER is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 777492. IMI2 receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views communicated within are those of PIONEER. Neither the IMI nor the European Union, EFPIA or any associated partners are responsible for any use that may be made of the information contained herein.

Publisher Copyright:
© 2023, Springer Nature Limited.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41585-023-00748-9

Cite this

the PIONEER Consortium, Omar, M. I., MacLennan, S., Ribal, M. J., Roobol, M. J., Dimitropoulos, K., van den Broeck, T., MacLennan, S. J., Axelsson, S. E., Gandaglia, G., Willemse, P. P., Mastris, K., Ransohoff, J. B., Devecseri, Z., Abbott, T., De Meulder, B., Bjartell, A., Asiimwe, A., N’Dow, J., ... Moinat, M. (2023). Unanswered questions in prostate cancer — findings of an international multi-stakeholder consensus by the PIONEER consortium. Nature Reviews Urology, 20(8), 494-501. https://doi.org/10.1038/s41585-023-00748-9

@article{33d89f91718845d5a2bb97326034e4b7,

title = "Unanswered questions in prostate cancer — findings of an international multi-stakeholder consensus by the PIONEER consortium",

abstract = "PIONEER is a European network of excellence for big data in prostate cancer consisting of 37 private and public stakeholders from 9 countries across Europe. Many progresses have been done in prostate cancer management, but unanswered questions in the field still exist, and big data could help to answer these questions. The PIONEER consortium conducted a two-round modified Delphi survey aiming at building consensus between two stakeholder groups — health-care professionals and patients with prostate cancer — about the most important questions in the field of prostate cancer to be answered using big data. Respondents were asked to consider what would be the effect of answering the proposed questions on improving diagnosis and treatment outcomes for patients with prostate cancer and to score these questions on a scale of 1 (not important) to 9 (critically important). The mean percentage of participants who scored each of the proposed questions as critically important was calculated across the two stakeholder groups and used to rank the questions and identify the highest scoring questions in the critically important category. The identification of questions in prostate cancer that are important to various stakeholders will help the PIONEER consortium to provide answers to these questions to improve the clinical care of patients with prostate cancer.",

author = "{the PIONEER Consortium} and Omar, {Muhammad Imran} and Steven MacLennan and Ribal, {Maria J.} and Roobol, {Monique J.} and Konstantinos Dimitropoulos and {van den Broeck}, Thomas and MacLennan, {Sara J.} and Axelsson, {Susan Evans} and Giorgio Gandaglia and Willemse, {Peter Paul} and Ken Mastris and Ransohoff, {John Butler} and Zsuzsanna Devecseri and Thomas Abbott and {De Meulder}, Bertrand and Anders Bjartell and Alex Asiimwe and James N{\textquoteright}Dow and Emma Smith and Karin Plass and Nicolas Mottet and Robert Shepherd and Lisa Moris and Michael Lardas and Nicola Fossati and Karl Pang and Riccardo Campi and Isabella Greco and Mauro Gacci and Sergio Serni and Ragnar Lonnerbro and Alberto Briganti and Daniele Crosti and Roberto Garzonio and Martina Faticoni and Chris Bangma and Eliza Roest and Arjan Breederland and Sebastiaan Remmers and Derya Tilki and Anssi Auvinen and Teemu Murtola and Tapio Visakorpi and Kirsi Talala and Teuvo Tammela and Aino Siltari and {Van Hemelrijck}, Mieke and Katharina Beyer and Stephane Lejeune and Maxim Moinat",

note = "Funding Information: PIONEER is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 777492. IMI2 receives support from the European Union{\textquoteright}s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views communicated within are those of PIONEER. Neither the IMI nor the European Union, EFPIA or any associated partners are responsible for any use that may be made of the information contained herein. Publisher Copyright: {\textcopyright} 2023, Springer Nature Limited.",

year = "2023",

month = aug,

doi = "10.1038/s41585-023-00748-9",

language = "English",

volume = "20",

pages = "494--501",

journal = "Nature Reviews Urology",

issn = "1759-4812",

publisher = "Nature Research",

number = "8",

}

the PIONEER Consortium, Omar, MI, MacLennan, S, Ribal, MJ, Roobol, MJ, Dimitropoulos, K, van den Broeck, T, MacLennan, SJ, Axelsson, SE, Gandaglia, G, Willemse, PP, Mastris, K, Ransohoff, JB, Devecseri, Z, Abbott, T, De Meulder, B, Bjartell, A, Asiimwe, A, N’Dow, J, Smith, E, Plass, K, Mottet, N, Shepherd, R, Moris, L, Lardas, M, Fossati, N, Pang, K, Campi, R, Greco, I, Gacci, M, Serni, S, Lonnerbro, R, Briganti, A, Crosti, D, Garzonio, R, Faticoni, M, Bangma, C, Roest, E, Breederland, A, Remmers, S, Tilki, D, Auvinen, A, Murtola, T, Visakorpi, T, Talala, K, Tammela, T, Siltari, A, Van Hemelrijck, M, Beyer, K, Lejeune, S & Moinat, M 2023, 'Unanswered questions in prostate cancer — findings of an international multi-stakeholder consensus by the PIONEER consortium', Nature Reviews Urology, vol. 20, no. 8, pp. 494-501. https://doi.org/10.1038/s41585-023-00748-9

TY - JOUR

T1 - Unanswered questions in prostate cancer — findings of an international multi-stakeholder consensus by the PIONEER consortium

AU - the PIONEER Consortium

AU - Omar, Muhammad Imran

AU - MacLennan, Steven

AU - Ribal, Maria J.

AU - Roobol, Monique J.

AU - Dimitropoulos, Konstantinos

AU - van den Broeck, Thomas

AU - MacLennan, Sara J.

AU - Axelsson, Susan Evans

AU - Gandaglia, Giorgio

AU - Willemse, Peter Paul

AU - Mastris, Ken

AU - Ransohoff, John Butler

AU - Devecseri, Zsuzsanna

AU - Abbott, Thomas

AU - De Meulder, Bertrand

AU - Bjartell, Anders

AU - Asiimwe, Alex

AU - N’Dow, James

AU - Smith, Emma

AU - Plass, Karin

AU - Mottet, Nicolas

AU - Shepherd, Robert

AU - Moris, Lisa

AU - Lardas, Michael

AU - Fossati, Nicola

AU - Pang, Karl

AU - Campi, Riccardo

AU - Greco, Isabella

AU - Gacci, Mauro

AU - Serni, Sergio

AU - Lonnerbro, Ragnar

AU - Briganti, Alberto

AU - Crosti, Daniele

AU - Garzonio, Roberto

AU - Faticoni, Martina

AU - Bangma, Chris

AU - Roest, Eliza

AU - Breederland, Arjan

AU - Remmers, Sebastiaan

AU - Tilki, Derya

AU - Auvinen, Anssi

AU - Murtola, Teemu

AU - Visakorpi, Tapio

AU - Talala, Kirsi

AU - Tammela, Teuvo

AU - Siltari, Aino

AU - Van Hemelrijck, Mieke

AU - Beyer, Katharina

AU - Lejeune, Stephane

AU - Moinat, Maxim

N1 - Funding Information: PIONEER is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 777492. IMI2 receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views communicated within are those of PIONEER. Neither the IMI nor the European Union, EFPIA or any associated partners are responsible for any use that may be made of the information contained herein. Publisher Copyright: © 2023, Springer Nature Limited.

PY - 2023/8

Y1 - 2023/8

N2 - PIONEER is a European network of excellence for big data in prostate cancer consisting of 37 private and public stakeholders from 9 countries across Europe. Many progresses have been done in prostate cancer management, but unanswered questions in the field still exist, and big data could help to answer these questions. The PIONEER consortium conducted a two-round modified Delphi survey aiming at building consensus between two stakeholder groups — health-care professionals and patients with prostate cancer — about the most important questions in the field of prostate cancer to be answered using big data. Respondents were asked to consider what would be the effect of answering the proposed questions on improving diagnosis and treatment outcomes for patients with prostate cancer and to score these questions on a scale of 1 (not important) to 9 (critically important). The mean percentage of participants who scored each of the proposed questions as critically important was calculated across the two stakeholder groups and used to rank the questions and identify the highest scoring questions in the critically important category. The identification of questions in prostate cancer that are important to various stakeholders will help the PIONEER consortium to provide answers to these questions to improve the clinical care of patients with prostate cancer.

AB - PIONEER is a European network of excellence for big data in prostate cancer consisting of 37 private and public stakeholders from 9 countries across Europe. Many progresses have been done in prostate cancer management, but unanswered questions in the field still exist, and big data could help to answer these questions. The PIONEER consortium conducted a two-round modified Delphi survey aiming at building consensus between two stakeholder groups — health-care professionals and patients with prostate cancer — about the most important questions in the field of prostate cancer to be answered using big data. Respondents were asked to consider what would be the effect of answering the proposed questions on improving diagnosis and treatment outcomes for patients with prostate cancer and to score these questions on a scale of 1 (not important) to 9 (critically important). The mean percentage of participants who scored each of the proposed questions as critically important was calculated across the two stakeholder groups and used to rank the questions and identify the highest scoring questions in the critically important category. The identification of questions in prostate cancer that are important to various stakeholders will help the PIONEER consortium to provide answers to these questions to improve the clinical care of patients with prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85151736991&partnerID=8YFLogxK

U2 - 10.1038/s41585-023-00748-9

DO - 10.1038/s41585-023-00748-9

M3 - Article

C2 - 37012441

AN - SCOPUS:85151736991

SN - 1759-4812

VL - 20

SP - 494

EP - 501

JO - Nature Reviews Urology

JF - Nature Reviews Urology

IS - 8

ER -

Unanswered questions in prostate cancer — findings of an international multi-stakeholder consensus by the PIONEER consortium

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this